Attendee search 

prmaconsulting offers best-in-class strategic and operational Pricing & Reimbursement, Market Access and Health Economics advice. We work for the majority of the top 15 Big Pharma companies, as well as in Biotech and Medtech.

Integrated Solutions from Research to Commercialisation.

Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.

Our vast range of services include:

Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory. 

API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.

Pharmaceutical Development:  Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.

Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.

Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.

Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.

Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.

 Almac – Partnering to Advance Human Health™

Integrated Solutions from Research to Commercialisation.

Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.

Our vast range of services include:

Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory. 

API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.

Pharmaceutical Development:  Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.

Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.

Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.

Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.

Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.

 Almac – Partnering to Advance Human Health™

NextPharma Technologies is a world class outsourcing partner to the pharmaceutical and biotechnology industries.

We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing of New Chemical Entities (NCEs) and generic products. NextPharma is a world leader in pellet technologies and in specialist product manufacturing including hormones, penicillins, cephalosporins and controlled drugs. We are experts in paediatric drug formulation, development and manufacture. In addition to these specialist areas we have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.

NextPharma offers ‘one-stop’ logistics solutions tailored to meet the needs of the global pharmaceutical industry under the rigid standards of cGSP/GDP regulations.

NextPharma operates globally with six product development centres, six manufacturing plants and seven temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.  We employ 1,000 people dedicated to serving over 200 customers world wide and a customer base, which includes many of the world’s leading pharmaceutical, specialty pharma and biotechnology companies.

All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.

Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.

- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.

The identified protein domains are then used to quickly develop binding/activity assays for use in small molecule hit screening. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging discovery programs. The Domainex services enhance drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.

BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.

Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.

- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.

The identified protein domains are then used to quickly develop binding/activity assays for use in small molecule hit screening. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging discovery programs. The Domainex services enhance drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.

Sera Laboratories International Ltd (Seralab) is an independent UK company providing a fast, friendly and efficient service with a focus on quality and traceability.

Seralab is a leading supplier of control matrices and disease state material from both human and animal models. The company offers the most complete range of human and animal-based research Bioproducts in Europe. Sera Lab provides serum, plasma, whole blood, tissues, microsomes, S9 fractions and fluids from the human model and an extensive range of animal species.

Our product range also includes Cell Culture sera and reagents including FBS, Cell Specific media selected growth factors and a range of standardised reagents and tools for all areas of Stem Cell research.

The Seralab technical and managerial team have, over 20 years, established an unrivalled reputation of working closely with our customers to develop individual, tailor made solutions; often through the development of new products and techniques.

Our commitment to traditional values of quality product, competitive pricing and absolute customer care are assured through our adherence to the spirit and application of ISO9001 accreditation, which we achieved in 2010. We constantly strive for service excellence providing reliability, full traceability and extensive quality control through customer led evolution and innovation.

Theryte is a drug discovery and development company that is committed to bringing revolutionary new cancer treatments to market.

Theryte's new approach targets the processes that normally stabilise the cancer cell, allowing the creation of novel, first-in-class anti-cancer drugs with a unique mechanism of action and efficacy against difficult-to-treat tumours.

Theryte aims to exploit its patented discoveries to: (i) develop the breakthrough technology to select pre-clinical candidates for partnering and licensing; (ii) advance a new family of anticancer targets for further drug development; and (iii) develop biomarkers to predict treatment response.